US2021317206A1PendingUtilityA1

Anti-human vista antibodies and use thereof

76
Assignee: IMMUNEXT INCPriority: Apr 15, 2016Filed: Mar 19, 2021Published: Oct 14, 2021
Est. expiryApr 15, 2036(~9.8 yrs left)· nominal 20-yr term from priority
Inventors:Michael MolloyJay Rothstein
A61K 38/16A61K 39/00C07K 14/705C07K 16/42C07K 16/46A61K 39/395C07K 2317/24C07K 2317/53C07K 2317/52C07K 2317/73C07K 2317/522A61P 31/00A61P 35/02A61P 35/00A61P 11/00C07K 2317/33C07K 2317/92C07K 2317/75A61P 25/00C07K 16/2803A61P 1/16A61P 13/12C07K 2317/74A61P 13/02A61K 2039/505A61P 19/02C07K 2317/76A61P 9/10A61P 37/06A61P 17/06C07K 2317/21C07K 16/2827A61K 45/06C07K 2317/34C07K 2317/31C07K 16/2896A61P 17/14A61P 39/02C07K 2317/565A61K 38/17A61P 17/00A61K 39/3955A61P 37/08A61P 1/00A61P 43/00A61P 37/02A61P 31/20A61P 29/00A61P 31/14Y02A50/30
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Claims

exact text as granted — not AI-modified
1 - 119 . (canceled) 
     
     
         120 . An isolated anti-human VISTA antibody or antibody fragment which:
 (i) comprises the V H  CDRs of SEQ ID NO:100, 101 and 102 and the V L  CDRs of SEQ ID NO:103, 104 and 105;   (ii) comprises the V H  CDRs of SEQ ID NO:110, 111 and 112 and the V L  CDRs of SEQ ID NO:113, 114 and 115;   (iii) comprises the V H  CDRs of SEQ ID NO:120, 121 and 122 and the V L  CDRs of SEQ ID NO:123, 124 and 125;   (iv) comprises the V H  CDRs of SEQ ID NO:130, 131 and 132 and the V L  CDRs of SEQ ID NO:133, 134 and 135;   (v) comprises the V H  CDRs of SEQ ID NO:140, 141 and 142 and the V L  CDRs of SEQ ID NO:143, 144 and 145;   (vi) comprises the V H  CDRs of SEQ ID NO:150, 151 and 152 and the V L  CDRs of SEQ ID NO:153, 154 and 155;   (vii) comprises the V H  CDRs of SEQ ID NO:160, 161 and 162 and the V L  CDRs of SEQ ID NO:163, 164 and 165;   (viii) comprises the V H  CDRs of SEQ ID NO:170, 171 and 172 and the V L  CDRs of SEQ ID NO:173, 174 and 175;   (ix) comprises the V H  CDRs of SEQ ID NO:180, 181 and 182 and the V L  CDRs of SEQ ID NO:183, 184 and 185;   (x) comprises the V H  CDRs of SEQ ID NO:190, 191 and 192 and the V L  CDRs of SEQ ID NO:193, 194 and 195;   (xi) comprises the V H  CDRs of SEQ ID NO:200, 201 and 202 and the V L  CDRs of SEQ ID NO:203, 204 and 205;   (xii) comprises the V H  CDRs of SEQ ID NO:210, 211 and 212 and the V L  CDRs of SEQ ID NO:213, 214 and 215;   (xiii) comprises the V H  CDRs of SEQ ID NO:220, 221 and 222 and the V L  CDRs of SEQ ID NO:223, 224 and 225;   (xiv) comprises the V H  CDRs of SEQ ID NO:230, 231 and 232 and the V L  CDRs of SEQ ID NO:233, 234 and 235;   (xv) comprises the V H  CDRs of SEQ ID NO:240, 241 and 242 and the V L  CDRs of SEQ ID NO:243, 244 and 245;   (xvi) comprises the V H  CDRs of SEQ ID NO:250, 251 and 252 and the V L  CDRs of SEQ ID NO:253, 254 and 255;   (xvii) comprises the VH CDRs of SEQ ID NO:260, 261 and 262 and the V L  CDRs of SEQ ID NO:263, 264 and 265;   (xviii) comprises the V H  CDRs of SEQ ID NO:270, 271 and 272 and the V L  CDRs of SEQ ID NO:273, 274 and 275;   (xix) comprises the V H  CDRs of SEQ ID NO:280, 281 and 282 and the V L  CDRs of SEQ ID NO:283, 284 and 285;   (xx) comprises the V H  CDRs of SEQ ID NO:290, 291 and 292 and the V L  CDRs of SEQ ID NO:293, 294 and 295;   (xxi) comprises the V H  CDRs of SEQ ID NO:300, 301 and 302 and the V L  CDRs of SEQ ID NO:303, 304 and 305;   (xxii) comprises the V H  CDRs of SEQ ID NO:310, 311 and 312 and the V L  CDRs of SEQ ID NO:313, 314 and 315;   (xxiii) comprises the V H  CDRs of SEQ ID NO:320, 321 and 322 and the V L  CDRs of SEQ ID NO:323, 324 and 325;   (xxiv) comprises the V H  CDRs of SEQ ID NO:330, 331 and 332 and the V L  CDRs of SEQ ID NO:333, 334 and 335;   (xxv) comprises the V H  CDRs of SEQ ID NO:340, 341 and 342 and the V L  CDRs of SEQ ID NO:343, 344 and 345;   (xxvi) comprises the V H  CDRs of SEQ ID NO:350, 351 and 352 and the V L  CDRs of SEQ ID NO:353, 354 and 355;   (xxvii) comprises the V H  CDRs of SEQ ID NO:360, 361 and 362 and the V L  CDRs of SEQ ID NO:363, 364 and 365;   (xxviii) comprises the V H  CDRs of SEQ ID NO:370, 371 and 372 and the V L  CDRs of SEQ ID NO:373, 374 and 375;   (xxix) comprises the V H  CDRs of SEQ ID NO:380, 381 and 382 and the V L  CDRs of SEQ ID NO:383, 384 and 385;   (xxx) comprises the V H  CDRs of SEQ ID NO:390, 391 and 392 and the V L  CDRs of SEQ ID NO:393, 394 and 395;   (xxxi) comprises the V H  CDRs of SEQ ID NO:400, 401 and 402 and the V L  CDRs of SEQ ID NO:403, 404 and 405;   (xxxii) comprises the V H  CDRs of SEQ ID NO:410, 411 and 412 and the V L  CDRs of SEQ ID NO:413, 414 and 415;   (xxxiii) comprises the V H  CDRs of SEQ ID NO:420, 421 and 422 and the V L  CDRs of SEQ ID NO:423, 424 and 425;   (xxxiv) comprises the V H  CDRs of SEQ ID NO:430, 431 and 432 and the V L  CDRs of SEQ ID NO:433, 434 and 435;   (xxxv) comprises the V H  CDRs of SEQ ID NO:440, 441 and 442 and the V L  CDRs of SEQ ID NO:443, 444 and 445;   (xxxvi) comprises the V H  CDRs of SEQ ID NO:450, 451 and 452 and the V L  CDRs of SEQ ID NO:453, 454 and 455;   (xxxvii) comprises the V H  CDRs of SEQ ID NO:460, 461 and 462 and the V L  CDRs of SEQ ID NO:463, 464 and 465;   (xxxviii) comprises the V H  CDRs of SEQ ID NO:470, 471 and 472 and the V L  CDRs of SEQ ID NO:473, 474 and 475;   (xxxix) comprises the V H  CDRs of SEQ ID NO:480, 481 and 482 and the V L  CDRs of SEQ ID NO:483, 484 and 485;   (xl) comprises the V H  CDRs of SEQ ID NO:490, 491 and 492 and the V L  CDR polypeptides of SEQ ID NO:493, 494 and 495;   (xli) comprises the V H  CDRs of SEQ ID NO:500, 501 and 502 and the V L  CDR polypeptides of SEQ ID NO:503, 504 and 505;   (xlii) comprises the V H  CDRs of SEQ ID NO:510, 511 and 512 and the V L  CDR polypeptides of SEQ ID NO:513, 514 and 515;   (xliii) comprises the V H  CDRs of SEQ ID NO:520, 521 and 522 and the V L  CDR polypeptides of SEQ ID NO:523, 524 and 525;   (xliv) comprises the V H  CDRs of SEQ ID NO:530, 531 and 532 and the V L  CDR polypeptides of SEQ ID NO:533, 534 and 535;   (xlv) comprises the V H  CDRs of SEQ ID NO:540, 541 and 542 and the V L  CDR polypeptides of SEQ ID NO:543, 544 and 545;   (xlvi) comprises the V H  CDRs of SEQ ID NO:550, 551 and 552 and the V L  CDR polypeptides of SEQ ID NO:553, 554 and 555;   (xlvii) comprises the V H  CDRs of SEQ ID NO:560, 561 and 562 and the V L  CDRs of SEQ ID NO:563, 564 and 565;   (xlviii) comprises the V H  CDRs of SEQ ID NO:570, 571 and 572 and the V L  CDRs of SEQ ID NO:573, 574 and 575;   (xlix) comprises the V H  CDRs of SEQ ID NO:580, 581 and 582 and the V L  CDRs of SEQ ID NO:583, 584 and 585;   (1) comprises the V H  CDRs of SEQ ID NO:590, 591 and 592 and the V L  CDRs of SEQ ID NO:593, 594 and 595;   (li) comprises the V H  CDRs of SEQ ID NO:600, 601 and 602 and the V L  CDRs of SEQ ID NO:603, 604 and 605;   (lii) comprises the V H  CDRs of SEQ ID NO:610, 611 and 612 and the V L  CDRs of SEQ ID NO:613, 614 and 615;   (liii) comprises the V H  CDRs of SEQ ID NO:620, 621 and 622 and the V L  CDRs of SEQ ID NO:623, 624 and 625;   (liv) comprises the V H  CDRs of SEQ ID NO:630, 631 and 632 and the V L  CDRs of SEQ ID NO:633, 634 and 635;   (lv) comprises the V H  CDRs of SEQ ID NO:640, 641 and 642 and the V L  CDRs of SEQ ID NO:643, 644 and 645;   (lvi) comprises the V H  CDRs of SEQ ID NO:650, 651 and 652 and the V L  CDRs of SEQ ID NO:653, 654 and 655;   (lvii) comprises the V H  CDRs of SEQ ID NO:660, 661 and 662 and the V L  CDRs of SEQ ID NO:663, 664 and 665;   (lviii) comprises the V H  CDRs of SEQ ID NO:670, 671 and 672 and the V L  CDRs of SEQ ID NO:673, 674 and 675;   (lix) comprises the V H  CDRs of SEQ ID NO:680, 681 and 682 and the V L  CDRs of SEQ ID NO:683, 684 and 685;   (lx) comprises the V H  CDRs of SEQ ID NO:690, 691 and 692 and the V L  CDRs of SEQ ID NO:693, 694 and 695;   (lxi) comprises the V H  CDRs of SEQ ID NO:700, 701 and 702 and the V L  CDRs of SEQ ID NO:703, 704 and 705;   (lxii) comprises the V H  CDRs of SEQ ID NO:710, 711 and 712 and the V L  CDRs of SEQ ID NO:713, 714 and 715;   (lxiii) comprises the V H  CDRs of SEQ ID NO:720, 721 and 722 and the V L  CDRs of SEQ ID NO:723, 724 and 725;   (lxiv) comprises the V H  CDRs of SEQ ID NO:730, 731 and 732 and the V L  CDRs of SEQ ID NO:733, 734 and 735;   (lxv) comprises the V H  CDRs of SEQ ID NO:740, 741 and 742 and the V L  CDRs of SEQ ID NO:743, 744 and 745;   (lxvi) comprises the V H  CDRs of SEQ ID NO:750, 751 and 752 and the V L  CDRs of SEQ ID NO:753, 754 and 755;   (lxvii) comprises the V H  CDRs of SEQ ID NO:760, 761 and 762 and the V L  CDRs of SEQ ID NO:763, 764 and 765;   (lxviii) comprises the V H  CDRs of SEQ ID NO:770, 771 and 772 and the V L  CDRs of SEQ ID NO:773, 774 and 775;   (lxix) comprises the V H  CDRs of SEQ ID NO:780, 781 and 782 and the V L  CDRs of SEQ ID NO:783, 784 and 785;   (lxx) comprises the V H  CDRs of SEQ ID NO:790, 791 and 792 and the V L  CDRs of SEQ ID NO:793, 794 and 795;   (lxxi) comprises the V H  CDRs of SEQ ID NO:800, 801 and 802 and the V L  CDRs of SEQ ID NO:803, 804 and 805; and   (lxxii) comprises the V H  CDRs of SEQ ID NO:810, 811 and 812 and the V L  CDRs of SEQ ID NO: 813, 814 and 815.   
     
     
         121 . An isolated antibody or antibody fragment which:
 (i) comprises the V H  polypeptide of SEQ ID NO:106 and the V L  polypeptide of SEQ ID NO:108;   (ii) comprises the V H  polypeptide of SEQ ID NO:116 and the V L  polypeptide of SEQ ID NO:118;   (iii) comprises the V H  polypeptide of SEQ ID NO:126 and the V L  polypeptide of SEQ ID NO:128;   (iv) comprises the V H  polypeptide of SEQ ID NO:136 and the V L  polypeptide of SEQ ID NO:138;   (v) comprises the V H  polypeptide of SEQ ID NO:146 and the V L  polypeptide of SEQ ID NO:148;   (vi) comprises the V H  polypeptide of SEQ ID NO:156 and the V L  polypeptide of SEQ ID NO:158;   (vii) comprises the V H  polypeptide of SEQ ID NO:166 and the V L  polypeptide of SEQ ID NO:168;   (viii) comprises the V H  polypeptide of SEQ ID NO:176 and the V L  polypeptide of SEQ ID NO:178;   (ix) comprises the V H  polypeptide of SEQ ID NO:186 and the V L  polypeptide of SEQ ID NO:188;   (x) comprises the V H  polypeptide of SEQ ID NO:196 and the V L  polypeptide of SEQ ID NO:198;   (xi) comprises the V H  polypeptide of SEQ ID NO:206 and the V L  polypeptide of SEQ ID NO:208;   (xii) comprises the V H  polypeptide of SEQ ID NO:216 and the V L  polypeptide of SEQ ID NO:218;   (xiii) comprises the V H  polypeptide of SEQ ID NO:226 and the V L  polypeptide of SEQ ID NO:228;   (xiv) comprises the V H  polypeptide of SEQ ID NO:236 and the V L  polypeptide of SEQ ID NO:238;   (xv) comprises the V H  polypeptide of SEQ ID NO:246 and the V L  polypeptide of SEQ ID NO:248;   (xvi) comprises the V H  polypeptide of SEQ ID NO:256 and the V L  polypeptide of SEQ ID NO:258;   (xvii) comprises the V H  polypeptide of SEQ ID NO:266 and the V L  polypeptide of SEQ ID NO:268;   (xviii) comprises the V H  polypeptide of SEQ ID NO:276 and the V L  polypeptide of SEQ ID NO:278;   (xix) comprises the V H  polypeptide of SEQ ID NO:286 and the V L  polypeptide of SEQ ID NO:288;   (xx) comprises the V H  polypeptide of SEQ ID NO:296 and the V L  polypeptide of SEQ ID NO:298;   (xxi) comprises the V H  polypeptide of SEQ ID NO:306 and the V L  polypeptide of SEQ ID NO:308;   (xxii) comprises the V H  polypeptide of SEQ ID NO:316 and the V L  polypeptide of SEQ ID NO:318;   (xxiii) comprises the V H  polypeptide of SEQ ID NO:326 and the V L  polypeptide of SEQ ID NO:328;   (xxiv) comprises the V H  polypeptide of SEQ ID NO:336 and the V L  polypeptide of SEQ ID NO:338;   (xxv) comprises the V H  polypeptide of SEQ ID NO:346 and the V L  polypeptide of SEQ ID NO:348;   (xxvi) comprises the V H  polypeptide of SEQ ID NO:356 and the V L  polypeptide of SEQ ID NO:358;   (xxvii) comprises the V H  polypeptide of SEQ ID NO:366 and the V L  polypeptide of SEQ ID NO:368;   (xxviii) comprises the V H  polypeptide of SEQ ID NO:376 and the V L  polypeptide of SEQ ID NO:378;   (xxix) comprises the V H  polypeptide of SEQ ID NO:386 and the V L  polypeptide of SEQ ID NO:388;   (xxx) comprises the V H  polypeptide of SEQ ID NO:396 and the V L  polypeptide of SEQ ID NO:398;   (xxxi) comprises the V H  polypeptide of SEQ ID NO:406 and the V L  polypeptide of SEQ ID NO:408;   (xxxii) comprises the V H  polypeptide of SEQ ID NO:416 and the V L  polypeptide of SEQ ID NO:418;   (xxxiii) comprises the V H  polypeptide of SEQ ID NO:426 and the V L  polypeptide of SEQ ID NO:428;   (xxxiv) comprises the V H  polypeptide of SEQ ID NO:436 and the V L  polypeptide of SEQ ID NO:438;   (xxxv) comprises the V H  polypeptide of SEQ ID NO:446 and the V L  polypeptide of SEQ ID NO:448;   (xxxvi) comprises the V H  polypeptide of SEQ ID NO:456 and the V L  polypeptide of SEQ ID NO:458;   (xxxvii) comprises the V H  polypeptide of SEQ ID NO:466 and the V L  polypeptide of SEQ ID NO:468;   (xxxviii) comprises the V H  polypeptide of SEQ ID NO:476 and the V L  polypeptide of SEQ ID NO:478;   (xxxix) comprises the V H  polypeptide of SEQ ID NO:486 and the V L  polypeptide of SEQ ID NO:488;   (xl) comprises the V H  polypeptide of SEQ ID NO:496 and the V L  polypeptide of SEQ ID NO:498;   (xli) comprises the V H  polypeptide of SEQ ID NO:506 and the V L  polypeptide of SEQ ID NO:508;   (xlii) comprises the V H  polypeptide of SEQ ID NO:516 and the V L  polypeptide of SEQ ID NO:518;   (xliii) comprises the V H  polypeptide of SEQ ID NO:526 and the V L  polypeptide of SEQ ID NO:528;   (xliv) comprises the V H  polypeptide of SEQ ID NO:536 and the V L  polypeptide of SEQ ID NO:533, 534 and 535;   (xlv) comprises the V H  polypeptide of SEQ ID NO:546 and the V L  polypeptide of SEQ ID NO:548;   (xlvi) comprises the V H  polypeptide of SEQ ID NO:556 and the V L  polypeptide of SEQ ID NO:558;   (xlvii) comprises the V H  polypeptide of SEQ ID NO:566 and the V L  polypeptide of SEQ ID NO:568;   (xlviii) comprises the V H  polypeptide of SEQ ID NO:576 and the V L  polypeptide of SEQ ID NO:578;   (xlix) comprises the V H  polypeptide of SEQ ID NO:586 and the V L  polypeptide of SEQ ID NO:588;   (1) comprises the V H  polypeptide of SEQ ID NO:596 and the V L  polypeptide of SEQ ID NO:598;   (li) comprises the V H  polypeptide of SEQ ID NO:606 and the V L  polypeptide of SEQ ID NO:608;   (lii) comprises the V H  polypeptide of SEQ ID NO:616 and the V L  polypeptide of SEQ ID NO:618;   (liii) comprises the V H  polypeptide of SEQ ID NO:626 and the V L  polypeptide of SEQ ID NO:628;   (liv) comprises the V H  polypeptide of SEQ ID NO:636 and the V L  polypeptide of SEQ ID NO:638;   (lv) comprises the V H  polypeptide of SEQ ID NO:646 and the V L  polypeptide of SEQ ID NO:648;   (lvi) comprises the V H  polypeptide of SEQ ID NO:656 and the V L  polypeptide of SEQ ID NO:658;   (lvii) comprises the V H  polypeptide of SEQ ID NO:666 and the V L  polypeptide of SEQ ID NO:668;   (lviii) comprises the V H  polypeptide of SEQ ID NO:676 and the V L  polypeptide of SEQ ID NO:678;   (lix) comprises the V H  polypeptide of SEQ ID NO:686 and the V L  polypeptide of SEQ ID NO:688;   (lx) comprises the V H  polypeptide of SEQ ID NO:696 and the V L  polypeptide of SEQ ID NO:698;   (lxi) comprises the V H  polypeptide of SEQ ID NO:706 and the V L  polypeptide of SEQ ID NO:708;   (lxii) comprises the V H  polypeptide of SEQ ID NO:716 and the V L  polypeptide of SEQ ID NO:718;   (lxiii) comprises the V H  polypeptide of SEQ ID NO:726 and the V L  polypeptide of SEQ ID NO:728;   (lxiv) comprises the V H  polypeptide of SEQ ID NO:736 and the V L  polypeptide of SEQ ID NO:738;   (lxv) comprises the V H  polypeptide of SEQ ID NO:746 and the V L  polypeptide of SEQ ID NO:748;   (lxvi) comprises the V H  polypeptide of SEQ ID NO:756 and the V L  polypeptide of SEQ ID NO:758;   (lxvii) comprises the V H  polypeptide of SEQ ID NO:766 and the V L  polypeptide of SEQ ID NO:768;   (lxviii) comprises the V H  polypeptide of SEQ ID NO:776 and the V L  polypeptide of SEQ ID NO:778;   (lxix) comprises the V H  polypeptide of SEQ ID NO:786 and the V L  polypeptide of SEQ ID NO:788;   (lxx) comprises the V H  polypeptide of SEQ ID NO:796 and the V L  polypeptide of SEQ ID NO:798;   (lxxi) comprises the V H  polypeptide of SEQ ID NO:806 and the V L  polypeptide of SEQ ID NO:808; and   (lxxii) comprises the V H  polypeptide of SEQ ID NO:816 and the V L  polypeptide of SEQ ID NO: 818.   
     
     
         122 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 120  which comprises a human IgG1, IgG2, IgG3 or IgG4 Fc region. 
     
     
         123 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 121  which comprises a human IgG1, IgG2, IgG3 or IgG4 Fc region. 
     
     
         124 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 120  which comprises a human IgG2 Fc region. 
     
     
         125 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 121  which comprises a human lgG2 Fc region. 
     
     
         126 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 120  which comprises a human IgG1, IgG2, IgG3 or IgG4 Fc region comprising at least one mutation which alters effector function. 
     
     
         127 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 121  which comprises a human IgG1, IgG2, IgG3 or IgG4 Fc region comprising at least one mutation which alters effector function. 
     
     
         128 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 120  which comprises a chimeric, human, multispecific or humanized antibody or antibody fragment. 
     
     
         129 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 121  which comprises a chimeric, human, multispecific or humanized antibody or antibody fragment. 
     
     
         130 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 120  which comprises a Fab, Fab2 or scFv. 
     
     
         131 . An isolated anti-human VISTA antibody or antibody fragment according to  claim 121  which comprises a Fab, Fab2 or scFv. 
     
     
         132 . A pharmaceutical composition comprising an isolated anti-human VISTA antibody or antibody fragment according to  claim 120  and a pharmaceutically acceptable carrier. 
     
     
         133 . A pharmaceutical composition comprising an isolated anti-human VISTA antibody or antibody fragment according to  claim 121  and a pharmaceutically acceptable carrier. 
     
     
         134 . A method of promoting T cell immunity in a subject in need thereof comprising administering an effective amount of an isolated anti-human VISTA antibody or antibody fragment according to  claim 120 , wherein said antibody does not comprise a human IgG2 Fc region having native FcγR binding. 
     
     
         135 . A method of promoting T cell immunity in a subject in need thereof comprising administering an effective amount of an isolated anti-human VISTA antibody or antibody fragment according to  claim 121 , wherein said antibody does not comprise a human IgG2 Fc region having native FcγR binding. 
     
     
         136 . The method of  claim 134 , wherein the subject has cancer or an infectious condition. 
     
     
         137 . The method of  claim 135 , wherein the subject has cancer or an infectious condition. 
     
     
         138 . A method of suppressing T cell immunity in a subject in need thereof comprising administering an effective amount of an isolated anti-human VISTA antibody or antibody fragment according to  claim 120 , wherein said antibody comprises a human IgG2 Fc region having native FcγR binding. 
     
     
         139 . A method of suppressing T cell immunity in a subject in need thereof comprising administering an effective amount of an isolated anti-human VISTA antibody or antibody fragment according to  claim 121 , wherein said antibody comprises a human IgG2 Fc region having native FcγR binding. 
     
     
         140 . The method of  claim 138 , wherein the subject has an autoimmune, inflammatory or allergic condition. 
     
     
         141 . The method of  claim 139 , wherein the subject has an autoimmune, inflammatory or allergic condition.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.